Trial
NCT03208127
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
—
Condition
End Stage Liver Disease
Intervention
Treatment with Direct Acting Antiviral tablet
Why stopped
Protocol transitioned to standard of care, no funding available to continue support of research work or data analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-28